Enfermedad por coronavirus 2019 (COVID-19)

Barra lateral del artículo

Contenido principal del artículo

Jorge Eliécer Sara Ochoa
María Claudia Sara Cueto
  • Biografía

    University of South Florida. Tampa, USA

Resumen

La infección respiratoria causada por el SARS-CoV-2 fue declarada pandemia por la OMS en marzo 11 de 2020. Este nuevo beta-coronavirus, producto probablemente de la mutación aleatoria de un coronavirus infectante de animales, ha impactado la humanidad, creado una gran mortalidad entre la población, y también ha desestabilizado la interacción entre los seres humanos y su calidad de vida. El trabajo conjunto de investigadores que han analizado los casos de COVID-19, los mecanismos biológicos, los efectos en el ser humano y las posibles vías de intervención conducen a exitosos avances científicos en el entendimiento de la infección, la creación de inmunidad y el uso de ciertos medicamentos, además de una novedosa e histórica forma de creación de nuevas vacunas eficientes y seguras. No se puede olvidar el esfuerzo en medidas de protección personal como el lavado de manos, higiene de superficies, distanciamiento social y equipos de protección, entre otras. En esta revisión narrativa analizamos algunos puntos importantes en el proceso infeccioso, manifestaciones clínicas, diagnóstico, manejo y prevención de la enfermedad por coronavirus 2019, COVID-19.

Palabras clave:
COVID-19, Infection, Mortality, signs and symptoms, laboratories, vaccination COVID-19, Infección, Mortalidad, signos y síntomas, laboratorios; vacunación COVID-19, Infecção, Mortalidade, signos e sintomas, laboratórios, vacinação

Detalles del artículo

Referencias

Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: History, mechanism, transmission, structural studies and therapeutics. Infection 2020; 49(2):199-213.

Dos Santos WG. Natural history of COVID-19 and current knowledge on treatment therapeutic options. Biomed Pharmacother. 2020;129:110493.

Zhou P, Lou YX, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med 2020;382:1199-207.

Zhang T, Wu Q, Zhang Z. Pangolin homology associated with 2019-nCoV. Bior xiv 2020;10.1101/2020.02.19.950253.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020;26:450-2.

Ortiz-Prado E, Simbaña-Rivera K, Barreno LG, Rubio-Neira M, Cevallos-Robalino D, Sanches-Sanmiguel H, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis 2020;98:115094.

Hozhabri H, Sparascio FP, Sohrabi H, Mousavifar L, Roy R, Scribano D, et al. The global emergency of novel coronavirus (SARS-CoV-2): An update of the current status and forecasting. Int J Environ Res Public Health 2020;17:1-35.

Mohapatra S, Menon NG, Mohapatra G, Pisharody L, Pattnaik A. The novel SARS-CoV-2 pandemic: Possible environmental transmission, detection, persistence and fate during wastewater and water treatment. Sci Total Environ. 2020;765:142746.

Dhama K, Khan S, Ruchi T, Shubhankar S, Sudipta B, Yashpal S, et al. Coronavirus Disease 2019–COVID-19. Clin Microbiol Rev 2020;33:e00028-20.

Muralidar S, Visaga S, Sekaran S. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 2020;179:85- 100.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444-8.

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019- nCoV spike in the prefusion conformation. Science 2020;367:1260-3.

Touma M. COVID-19: Molecular diagnostics overview. J Mol Med 2020;98:947-54.

Wang H, Li X, Li T, Zhang S, Wang L, Wu X, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020;39:1629-35.

Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ 2020;371:1-6.

Galloway SE, Paul P, MacCannell D, Johansson M, Brooks J, MacNeil A. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021. US Dep Heal Hum Serv Dis Control Prev 2021;70:95-9.

Tang JW, Toovey OTR, Harvey KN, Hui DDS. Introduction of the South African SARS-CoV-2 variant 501Y. V2 into the UK. J Infect 2021;14:337-9.

Nascimento VAD, Corado ALG, Nascimento FOD, Costa ÁKAD, Duarte DCG, Luz SLB, et al. Genomic and phylogenetic characterisation of an imported case of Sars-Cov-2 in Amazonas state, Brazil. Mem Inst Oswaldo Cruz 2020;115:1-6.

Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P, et al. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Infect Dis Poverty 2020;9:1-11.

Iser BPM, Sliva I, Raymundo VT, Poleto MB, Schuelter-Trevisol F, Bobinski F. Suspected COVID-19 case definition: A narrative review of the most frequent signs and symptoms among confirmed cases. Rev Sist Unico Saude Bras 2020;29:e2020233.

Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42.

Ladecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. Cell 2020;183:16-27.e1.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;323:1061-9.

Li C, Tang B, Wang Y, Gu B. Laboratory diagnosis of Coronavirus Disease-2019 (COVID-19). Clin Chim Acta 2020;510:35-46.

Yu F, Yan L, Wang N, Yang S, Wang L, Tang Y, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis 2020;71:793-8.

Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clin Chim Acta 2020;510:475-82.

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe Coronavirus Disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020;506:145-8.

Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Ndieugnou N, Peluso L, Talamonti M, Izzi A, Gevenois PA, Garufi A, et al. Eosinopenia in COVID-19 patients: A retrospective analysis. Microorganisms 2020;8:1-12.

Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH. Eosinopenia and COVID-19. J Am Osteopath Assoc 2020;120:504-8.

Tan Y, Zhou J, Zhou Q, Hu L, Long Y. Role of eosinophils in the diagnosis and prognostic evaluation of COVID-19. J Med Virol. 2020:93:1105-10.

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: A comprehensive review. J Intern Med 2020;288:192-206.

Bernheim A, Mei X, Huang M, Yang Y, Fayad Z, Zhang N, et al. Chest CT findings in Coronavirus Disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020;295:200463.

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review. JAMA 2020;324:782- 93.

The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med 2020;384:693-704.

Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA 2020;324:1307-16.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 — final report. N Engl J Med 2020;383:1813-26.

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2020;384:795-807.

Simonovich VA, Burgos LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2020;384:619-29.

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA 2020;324:460-70.

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71:732-9.

Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al. A cluster-randomized trial of hydroxychloroquine for prevention of COVID-19. N Engl J Med 2020;384:417-27.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate Coronavirus disease 2019: Open label, randomized controlled trial. BMJ 2020;369:m1849.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020;178:337-9.

Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis 2020;79:1286-9.

Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized With Coronavirus disease 2019: The GRECCO-19 randomized clinical trial. JAMA 2020;3:e2013136.

Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: A systematic review. Plos One. 2012;7:e35797.

Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020;383:2439-50.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603-15.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA- 1273 SARS-CoV-2 vaccine. N Engl J Med 2020;384:403-16.

Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020;383:2320-32.

Artículos más leídos del mismo autor/a